The subscription period for a preference share issue in CombiGene AB (“CombiGene” or “the Company”) amounting

The Board of Directors of CombiGene AB (publ) (”CombiGene” or ”the Company”) has approved a proposal

CombiGene AB realized a preference share issue in February 2018. The issue raised 2.3 million kronor

The preference share issue, realized during the period 12 February – 28 February 2018, was subscribed

CombiGene had a very intensive year in 2017, with three successful preclinical studies. Thanks to the

The Board of Directors of CombiGene AB (publ) (”CombiGene” or ”the Company”) has approved a proposal

Som en följd av den nyligen genomförda företrädesemissionen i  CombiGene AB har Lars Thunbergs ägarandel i

Not for release, publication or distribution, directly or indirectly, in or into the United States,  Australia,